Balasagrathita ↔ Scleritis

Balasagrathita's deeper, bound, more severe character maps onto scleritis, a genuine marker of systemic autoimmune disease -- most commonly rheumatoid arthritis -- that can progress to scleromalacia perforans. The source explicitly states that local classical measures here have, at best, a limited adjunct role, calling this the clearest instance in the entire course of a principle it names outright: local eye treatment must never substitute for, or delay, the systemic treatment a serious finding demands.

IN PLAIN LANGUAGE

Severe, deep, boring eye pain that can radiate to the jaw or temple and wake you at night, with a violet-red tinge and marked tenderness. This is a warning sign not just for the eye but often for an underlying autoimmune disease, most commonly rheumatoid arthritis, that needs its own treatment.

The classical framework correctly recognized this as a more severe, deeper, more dangerous condition than its paired diagnosis (Sirajalaka/episcleritis) and named it with a distinctly heavier, 'bound' quality. Modern medicine's essential contribution is identifying the specific systemic autoimmune associations, offering systemic immunosuppressive treatment, and coordinating rheumatology care -- treatment the classical local framework alone cannot supply and, per the source, must not substitute for.

WHEN TO SEEK CARE

Any severe, deep eye pain radiating to the face, waking you at night, with marked tenderness over the eye needs urgent ophthalmology assessment. This often requires investigation for an underlying systemic disease, not eye treatment alone.

🔴 REFER IMMEDIATELY

Severe, deep, boring eye pain radiating to the jaw, temple or face, especially waking the patient at night
Marked tenderness to palpation over the globe, or a violaceous/blue-purple hue to the redness
Reduced visual acuity accompanying eye pain and redness
Persistent redness despite topical phenylephrine application (fails to blanch)
Known or newly suspected autoimmune/connective tissue disease (rheumatoid arthritis, granulomatosis with polyangiitis, systemic lupus erythematosus, relapsing polychondritis, inflammatory bowel disease) presenting with eye pain
Signs of scleral thinning, or a history of longstanding, inadequately treated disease (risk of scleromalacia perforans and globe perforation)
Any confirmed or strongly suspected scleritis
Any of the red-flag features listed above
Any patient with known autoimmune disease presenting with new eye pain

Never do this

Do not treat confirmed or suspected scleritis with Lekhana, Kshara, Raktamokshana, or any local classical measure as the first, sole, or definitive treatment. Per the source, this is explicitly stated as the course's clearest instance of local measures needing to never substitute for or delay systemic treatment -- untreated or inadequately treated disease, especially necrotizing scleritis, can progress to scleromalacia perforans and globe perforation, and carries real systemic morbidity and mortality risk from the underlying autoimmune disease itself.

🟢 SUITABLE FOR ROUTINE / COLLABORATIVE CARE

AYURVEDA SCOPE

At most a limited adjunct role for local vascular engorgement (Lekhana, Kshara, Raktamokshana) alongside -- never instead of -- systemic treatment, once scleritis is confirmed and systemic management is underway.

MODERN MEDICINE SCOPE

Systemic (not topical) NSAID for mild disease; systemic corticosteroid and steroid-sparing immunosuppressive agents for moderate-to-severe or necrotizing disease; investigation for and co-management of underlying autoimmune/connective tissue disease with rheumatology.

COLLABORATIVE SCOPE

None beyond ensuring any practitioner first encountering this presentation recognizes it as a possible systemic-disease marker and arranges urgent ophthalmic and, where indicated, rheumatological assessment rather than beginning local classical treatment as a first or sole response.

Sign in to read the full comparison

The plain-language summary and safety guidance above are free for everyone. The 10-dimension scholarly comparison needs an account.